We are live on ! Find out more
CRL icon

Charles River Laboratories

633 hedge funds and large institutions have $12.4B invested in Charles River Laboratories in 2023 Q4 according to their latest regulatory filings, with 94 funds opening new positions, 204 increasing their positions, 258 reducing their positions, and 70 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more funds holding in top 10

Funds holding in top 10: 38 (+5)

34% more first-time investments, than exits

New positions opened: 94 | Existing positions closed: 70

22% more capital invested

Capital invested by funds: $10.1B → $12.4B (+$2.25B)

2% more funds holding

Funds holding: 621633 (+12)

1.21% more ownership

Funds ownership: 101.05%102.25% (+1.2%)

21% less repeat investments, than reductions

Existing positions increased: 204 | Existing positions reduced: 258

32% less call options, than puts

Call options by funds: $54.7M | Put options by funds: $80.5M

Holders
633
Holders Change
+12
Holders Change %
+1.93%
% of All Funds
9.23%
Holding in Top 10
8
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+166.67%
% of All Funds
0.12%
New
94
Increased
204
Reduced
258
Closed
70
Calls
$54.7M
Puts
$80.5M
Net Calls
-$25.8M
Net Calls Change
-$3.78M
Name Holding Trade Value Shares
Change
Change in
Stake
AQR Capital Management
101
AQR Capital Management
Connecticut
$17.3M -$2.29M -11,643 -14%
RP
102
Reinhart Partners
Wisconsin
$17.2M -$3.18M -16,174 -18%
NC
103
Nicholas Company
Wisconsin
$16.7M +$2.1M +10,695 +18%
Baillie Gifford & Co
104
Baillie Gifford & Co
United Kingdom
$16.6M -$1.84M -9,370 -12%
IHL
105
Investment House LLC
California
$16.1M -$139K -706 -1%
DDC
106
DF Dent & Co
Maryland
$16M +$3.74M +19,023 +39%
Natixis Advisors
107
Natixis Advisors
Massachusetts
$15.8M +$1.36M +6,913 +12%
Tudor Investment Corp
108
Tudor Investment Corp
Connecticut
$15.6M +$1.72M +8,744 +15%
PAS
109
Professional Advisory Services
Florida
$15.5M +$686K +3,487 +6%
IHAM
110
Integral Health Asset Management
New York
$15.4M +$12.8M +65,000 New
Amundi
111
Amundi
France
$15.2M +$5.09M +25,896 +58%
ACM
112
Argent Capital Management
Missouri
$14.6M -$18.5M -93,821 -60%
FLPIM
113
F.L. Putnam Investment Management
Massachusetts
$14.6M +$844K +4,293 +7%
CI
114
Cambiar Investors
Colorado
$14.2M +$1.9M +9,651 +19%
VanEck Associates
115
VanEck Associates
New York
$13.6M -$1.07M -5,418 -9%
HSBC Holdings
116
HSBC Holdings
United Kingdom
$13.3M -$1.39M -7,068 -11%
GKIM
117
GW&K Investment Management
Massachusetts
$13.1M +$1.92M +9,782 +21%
LKIM
118
Lawson Kroeker Investment Management
Nebraska
$13.1M -$2.56K -13 -0%
2
119
2Xideas
Switzerland
$13M -$682K -3,467 -6%
New York State Teachers Retirement System (NYSTRS)
120
New York State Teachers Retirement System (NYSTRS)
New York
$13M -$339K -1,724 -3%
Lazard Asset Management
121
Lazard Asset Management
New York
$12.8M +$446K +2,269 +4%
State Board of Administration of Florida Retirement System
122
State Board of Administration of Florida Retirement System
Florida
$12.8M +$695K +3,536 +7%
CWM
123
Congress Wealth Management
Massachusetts
$12.7M +$59.4K +302 +0.6%
Millennium Management
124
Millennium Management
New York
$12.5M +$3.8M +19,334 +58%
FCM
125
Frontier Capital Management
Massachusetts
$12.1M +$730K +3,711 +8%

CRL Hedge Fund Activity: Q4 2023 in Review

633 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q4 2023, worth a combined $12.4B — up 22% from $10.1B a quarter earlier.

Buyers outnumbered sellers: 94 funds opened new CRL positions and 70 closed out — a net gain of 24 holders — while 204 added to existing stakes and 258 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $82.4M. The largest seller was Fidelity Investments, cutting an estimated $103M.

  • 633 institutional investors held Charles River Laboratories (CRL) as of Q4 2023, up from 621 in Q3 2023.
  • Funds reported $12.4B of Charles River Laboratories stock for Q4 2023, up 22% quarter-over-quarter.
  • 94 funds opened new Charles River Laboratories positions in Q4 2023 and 70 closed out, a net change of +24 holders.
  • The largest Charles River Laboratories buyer in Q4 2023 was Morgan Stanley, an estimated $82.4M added.
  • The largest Charles River Laboratories seller in Q4 2023 was Fidelity Investments, an estimated $103M sold.

Based on aggregated 13F filings for Q4 2023.